Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Before it's even submitted for FDA review, Eli Lilly's next-gen weight-loss drug retatrutide has spawned a thriving black market fueled by social media influencers, med spas, and online vendors. Lilly has filed six lawsuits and referred thousands of sellers to regulators, but enforcement remains hamstrung by limited FDA resources. Clinicians are left grappling with patients who are already using unverified, potentially dangerous knockoffs.
Eli Lilly's investigational weight-loss drug retatrutide — a once-weekly injectable shown to help people lose up to 30% of their body weight — hasn't even been submitted for FDA approval, yet it's already at the center of a sprawling black market. Social media influencers are touting knockoffs dubbed "r3ta" or "triple G," more than 120 websites are selling or promoting the drug, and at least 50 clinics staffed by licensed providers are openly advertising it. Lilly has filed six lawsuits against med spas, compounding pharmacies, and other vendors, and has referred thousands of sellers to regulators and law enforcement.
Despite FDA warning letters to 14 vendors since December 2024, most continued advertising or selling the drug. Enforcement has stalled at the warning letter stage, with experts noting the agency lacks the resources — and congressional funding — to pursue seizures or injunctions. Clinicians are divided on how to handle patients already using unverified products, with some counseling patients to wait for FDA approval while closely monitoring labs, and others refusing to prescribe or refer.
Key Takeaways:
Why it matters: The retatrutide black market is a preview of what happens when patient demand for breakthrough therapies outpaces regulatory infrastructure — putting consumers at serious risk and leaving frontline clinicians without clear guidance.
